Skip to main content

Table 2 Provision of cancer care to breast cancer patients without distant metastasis by age

From: Provision of breast cancer care and survival in Germany – results from a population-based high resolution study from Saarland

Treatment

Category

Overall

 

15-69 years

 

> = 70 years

 
  

N

%

N

%

N

%

Overall

 

4025

 

2691

 

1334

 

Local treatment

Available

3038

75.5

2078

77.2

960

72.0

 

BCSa

316

10.4

187

9.0

129

13.4

 

BCS + radiotherapya

1716

56.5

1342

64.6

374

39.0

 

Mastectomya

558

18.4

262

12.6

296

30.8

 

Mastectomy + radiotherapya

424

14.0

284

13.7

140

14.6

 

No surgerya

24

0.8

3

0.1

21

2.2

Lymph node dissection

Available

3043

75.6

2145

79.7

898

67.3

 

ALNDa

1274

41.9

812

37.9

462

51.4

 

SNDa

1139

37.4

849

39.6

290

32.3

 

SND + ALNDa

525

17.3

432

20.1

93

10.4

 

Nonea

47

1.5

7

0.3

40

4.5

Chemotherapyb

Available

1571

86.2

1154

91.4

417

74.5

 

Yesa

1215

77.3

1050

91.0

165

39.6

 

Nonea

356

22.7

104

9.0

252

60.4

Antiestrogen treatmentc

Available

2232

75.8

1556

80.0

676

67.6

 

Yesa

2035

91.2

1433

92.1

602

89.1

 

Nonea

197

8.8

123

7.9

73

10.9

Targeted therapyd

Available

443

55.7

325

58.9

118

48.4

 

Yesa

188

42.4

164

50.5

24

20.3

 

Nonea

255

57.6

161

49.5

94

79.7

  1. Local treatment, lymph node dissection and adjuvant systemic treatment of female BRC patients without distant metastases (ICD-10: C50) from Saarland diagnosed between 2005 and 2009. BCS: breast conserving surgery; ALND: axillary lymph node dissection; SND: sentinel node dissection; a) proportions among patients with available information; b) among patients with positive lymph nodes or hormone receptor negative tumors; c) among patients with hormone receptor positive or mixed tumors; d) among patients with HER2/neu expressed tumors; patients presenting with distant metastases or DCO notified tumors were excluded.